Fournier's gangrene mortality: A 17-year systematic review and meta-analysis.

Published
January 22, 2020
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
PICOID
e7bc139a
DOI
Citations
66
Keywords
Fournier’s gangrene, Mortality, Systematic review
Copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Patients/Population/Participants

patients with Fournier's gangrene

Intervention

systematic search and meta-analysis of relevant articles

Comparison

comorbidities and common etiologies vs. no comorbidities

Outcome

mortality rates and risk ratios

Abstract

P
I
C
O

To provide better management of Fournier's gangrene, mortality-associated comorbidities and common etiologies were identified. A systematic search was conducted using 12 databases, followed by meticulous screening to select relevant articles. Meta-analysis and meta-regression (for possible cofounders) were both done for all possible outcomes. Out of 1186 reports screened, 38 studies were finally included in the systematic review and meta-analysis. A higher risk of mortality was detected in patients with diabetes, heart disease, renal failure, and kidney disease, with risk ratios (RR) and 95% confidence intervals (95% CI) of 0.72 (0.59-0.89), 0.39 (0.24-0.62), 0.41 (0.27-0.63), and 0.34 (95% CI 0.16-0.73), respectively. However, there was no association between mortality rates and comorbid hypertension, lung disease, liver disease, or malignant disease (p > 0.05). The highest mortality rates were due to sepsis (76%) and multiple organ failure (66%), followed by respiratory (19.4%), renal (18%), cardiovascular (15.7%), and hepatic (5%) mortality. Modifications to the Fournier's Gangrene Severity Index (FGSI) are recommended, in order to include comorbidities as an important prognostic tool for FG mortality. Close monitoring of the patients, with special interest given to the main causes of mortality, is an essential element of the management process.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.